Cost Effective Drugs
- All
- News
- Videos
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
GLP-1 Users Often Restart Medication After Stopping, Finds Study; What Exactly Happens After Quitting?
The study found that a significant portion of patients who discontinued the drug actually went back to treatment within a year.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Doctors Tell Soha Ali Khan Price Of Mounjaro After Aishwarya Mohanraj's Video
The cost of weight-loss drugs has reduced, and according to the experts, it will continue to come down
-
6-Month Drug-Resistant Tuberculosis Treatment More Effective, Cheaper Than Existing Regimens: ICMR Study
The ICMR analysis found that the BPaL regimen is "both more effective and cost-saving" compared to the current standard of care.
-
Tuberculosis: Short 6-Month Oral Treatment Plan Proves Affordable In India
Shorter, six month and alloral treatment regimens for multidrugresistant and rifampicinresistant tuberculosis (MDR/RRTB) are costeffective and deliver better health outcomes than longer regimens.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Can Non-Diabetics Take Ozempic For Weight Loss? Doctor Answers
Ozempic is the brand name for a medication called semaglutide, which is primarily used to manage type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
GLP-1 Users Often Restart Medication After Stopping, Finds Study; What Exactly Happens After Quitting?
The study found that a significant portion of patients who discontinued the drug actually went back to treatment within a year.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Doctors Tell Soha Ali Khan Price Of Mounjaro After Aishwarya Mohanraj's Video
The cost of weight-loss drugs has reduced, and according to the experts, it will continue to come down
-
6-Month Drug-Resistant Tuberculosis Treatment More Effective, Cheaper Than Existing Regimens: ICMR Study
The ICMR analysis found that the BPaL regimen is "both more effective and cost-saving" compared to the current standard of care.
-
Tuberculosis: Short 6-Month Oral Treatment Plan Proves Affordable In India
Shorter, six month and alloral treatment regimens for multidrugresistant and rifampicinresistant tuberculosis (MDR/RRTB) are costeffective and deliver better health outcomes than longer regimens.
-
Ozempic Enters India: Diabetes Drug, Not A Miracle Fix, Novo Nordisk MD To NDTV
In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.
-
Can Non-Diabetics Take Ozempic For Weight Loss? Doctor Answers
Ozempic is the brand name for a medication called semaglutide, which is primarily used to manage type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists
